Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.

FitzGerald GA, Brash AR, Oates JA, Pedersen AK
J Clin Invest. 1983 72 (4): 1336-43

PMID: 6355181 · PMCID: PMC370417 · DOI:10.1172/JCI111089

The consequences of inhibiting the metabolism of prostaglandin G2 to thromboxane A2 in man were studied by using an inhibitor of thromboxane synthase, 4-[2-(IH-imidazol-1-yl)ethoxy] benzoic acid hydrochloride (dazoxiben). Single doses of 25, 50, 100, and 200 mg of dazoxiben were administered to healthy volunteers at 2-wk intervals in a randomized, placebo-controlled, double-blind manner. Serum thromboxane B2 and aggregation studies in whole blood and platelet-rich plasma were measured before dosing and at 1, 4, 6, 8, and 24 h after dosing. Both serum thromboxane B2 and the platelet aggregation response to arachidonic acid (1.33 mM) were reversibly inhibited in a dose-dependent manner. Aggregation induced by 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (0.4 and 4.0 microM) in platelet-rich plasma as well as both aggregation and nucleotide release induced by collagen (95 micrograms/ml) in platelet-rich plasma and whole blood were unaltered by dazoxiben. Additional evidence for a platelet-inhibitory effect of the compound was a significant prolongation of the bleeding time at 1 h after administration of the highest dose (200 mg) of dazoxiben. Endogenous prostacyclin biosynthesis was assessed by measurement of the major urinary metabolite of prostacyclin, 2,3-dinor-6-keto-PGF1 alpha (PGI-M). PGI-M excretion was increased by dazoxiben; it rose a mean 2.4-fold from predosing control values at 0-6 h after administration of the highest dose studied (200 mg).

MeSH Terms (13)

Adult Bleeding Time Depression, Chemical Dose-Response Relationship, Drug Epoprostenol Humans Imidazoles Male Oxidoreductases Platelet Aggregation Prostaglandins F, Synthetic Thromboxane-A Synthase Thromboxane B2

Connections (1)

This publication is referenced by other Labnodes entities: